Last reviewed · How we verify
Topamax® Sprinkle Capsules 25 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Topamax® Sprinkle Capsules 25 mg (Topamax® Sprinkle Capsules 25 mg) — Mylan Pharmaceuticals Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Topamax® Sprinkle Capsules 25 mg TARGET | Topamax® Sprinkle Capsules 25 mg | Mylan Pharmaceuticals Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Topamax® Sprinkle Capsules 25 mg CI watch — RSS
- Topamax® Sprinkle Capsules 25 mg CI watch — Atom
- Topamax® Sprinkle Capsules 25 mg CI watch — JSON
- Topamax® Sprinkle Capsules 25 mg alone — RSS
Cite this brief
Drug Landscape (2026). Topamax® Sprinkle Capsules 25 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/topamax-sprinkle-capsules-25-mg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab